Gritstone Oncology, Inc. (GRTS) Social Stream
GRITSTONE BIO INC (GRTS) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering GRTS.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
GRTS's average price target has moved down $15.83 over the prior 34 months.
GRTS reports an average of 203.16% for its upside potential over the past 44 weeks.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
GRTS Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 36 months, GRTS's average broker recommendation rating worsened by 0.57.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for GRTS as an investment opportunity.
- GRTS has a greater number of analysts covering the stock than 115.33% of all US stocks.
- GRITSTONE BIO INC's upside potential (average analyst target price relative to current price) is greater than 875.78% of all US stocks.
- In terms of how GRITSTONE BIO INC fares relative to all US stocks, note that its average analyst price target is higher than 149.2% of that group.
- In the context of Pharmaceutical Products stocks, GRITSTONE BIO INC's variance in analysts' estimates is lower than -423.99% of them.
In the Pharmaceutical Products industry, STRO, AUTL, and AVRO are the three stocks most similar to GRITSTONE BIO INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Make investment decisions regarding GRTS using the data that counts. Try POWR Ratings for free.